Peter Attia, M.D., has been vocal about this concern: the scale going down is not inherently good if the composition of that weight loss is working against your long-term metabolic health
This is different level
Contrastingly, GLP1 antagonist sales in 2023 showcase a more diversified landscape, with therapeutics such as Ozempic, Trulicity, and Mounjaro driving 71 per cent of the sales. Looking ahead, the GLP1 agonist market is poised for robust growth, anticipating a 19.2 per cent compound annual growth rate (CAGR) from 2023 to 2029, reaching a substantial market size of $105 billion in 2029
During acute infection, plasma levels of vitamin C are reduced due to increased metabolic demands (160, 162)
Therefore, causality cannot be attributed to semaglutide
We want to make sure you get exactly the right amount for you, but not too much